Lifecore Biomedical, Inc. De (LFCR) EV to EBITDA (2010 - 2025)

Lifecore Biomedical has reported EV to EBITDA for 16 years, with the latest figure at 45.16 in Q2 2025.

• On a quarterly basis, EV to EBITDA fell 40.57% year-over-year to 45.16 in Q2 2025; TTM through May 2025 was 13.95, a 24.46% increase from a year earlier, with the FY2025 full-year figure at 13.95, up 24.46% from the prior year.
• EV to EBITDA was 45.16 for Q2 2025 at Lifecore Biomedical, up from 22.41 in the prior quarter.
• The five-year high for EV to EBITDA was 4453.4 in Q1 2021, with the low at 275.43 in Q1 2024.
• Average EV to EBITDA over 5 years is 196.44, with a median of 34.29 recorded in 2022.
• The sharpest annual moves came in 2021 and 2024: EV to EBITDA jumped 19967.0% in 2021, then slumped 931.36% in 2024.
• Over 5 years, EV to EBITDA stood at 69.1 in 2021, then plunged by 166.96% to 46.27 in 2022, then sank by 233.35% to 154.25 in 2023, then grew by 13.67% to 133.17 in 2024, then soared by 133.91% to 45.16 in 2025.
• The last three EV to EBITDA figures came in at 45.16 (Q2 2025), 22.41 (Q1 2025), and 133.17 (Q4 2024), per Business Quant data.